百济神州(06160.HK)宣布百悦泽®一线治疗套细胞淋巴瘤的 3期临床研究取得积极结果

智通财经
Jun 30
【百济神州(06160.HK)宣布百悦泽®一线治疗套细胞淋巴瘤的 3期临床研究取得积极结果】智通财经APP讯,百济神州(06160.HK)公布,MANGROVE 3期临床研究(BGB-3111-306;NCT04002297)取得积极结果。该研究旨在评估公司自主研发的基石性产品BTK抑制剂百悦泽® (泽布替尼)联合利妥昔单抗,对照苯达莫司汀联合利妥昔单抗(BR),用于套细胞淋巴瘤(MCL)成人初治患者一线治疗的效果。MANGROVE是首个在该治疗场景下评估基于BTK抑制剂的无化疗方案对比标准免疫化疗方案的全球性、随机3期临床研究。该关键性3期临床研究的积极结果有望巩固泽布替尼在MCL疾病领域中的临床证据基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10